The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
 
Scott S. Tykodi
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending (Inst)
 
Frede Donskov
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Cezary Szczylik
No Relationships to Disclose
 
Jahangeer Malik
No Relationships to Disclose
 
Boris Yakovlevich Alekseev
Research Funding - Merck
 
James M.G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Vsevolod Borisovich Matveev
Consulting or Advisory Role - Bayer; Eisai
Travel, Accommodations, Expenses - Bayer (I)
 
Rustem Gafanov
No Relationships to Disclose
 
Piotr Tomczak
No Relationships to Disclose
 
Poul F. Geertsen
Research Funding - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Pawel J. Wiechno
No Relationships to Disclose
 
Sang Joon Shin
No Relationships to Disclose
 
Frederic Pouliot
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Genzyme; Janssen; Roche; Sanofi
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Genzyme; Janssen; Sanofi
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; Bayer; Genzyme; Janssen; Sanofi
 
Teresa Alonso-Gordoa
Honoraria - Astellas Pharma; Janssen; Novartis; Pfizer; Roche; Sanofi
Research Funding - Roche
 
Rachel Kloss Silverman
Employment - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; X4 Pharma
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center; Various
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)